

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-65)

PEGCANTRATINIB

PRONUNCIATION

peg'' can tra tin' ib


THERAPEUTIC CLAIM

Topical treatment of pruritus associated with psoriasis vulgaris

CHEMICAL NAMES

1. Poly(oxy-1,2-ethanediyl),  $\alpha$ -methyl- $\omega$ -[2-[(5'*R*,9*S*,12*R*)-2,3,11,12-tetrahydro-9-methyl-1,2',4'-trioxospiro[9,12-epoxy-1*H*-diindolo[1,2,3-*fg*:3',2',1'-*k*]pyrrolo[3,4-*l*][1,6]benzodiazocine-10(9*H*),5'-oxazolidin]-3'-yl]ethoxy]-
2. (5'*R*,9*S*,12*R*)-9-methyl-3'-[ $\alpha$ -methylpoly(oxyethylene)]-2,3,11,12-tetrahydro-1*H*,9*H*-spiro[9,12-epoxydiindolo[1,2,3-*fg*:3',2',1'-*k*]pyrrolo[3,4-*l*][1,6]benzodiazocine-10,5'-oxazolidine]-1,2',4'-trione

STRUCTURAL FORMULA



MOLECULAR FORMULA

$C_{28}H_{20}N_4O_5[C_2H_4O]_n$

MOLECULAR WEIGHT

$\approx 2.5$  kDa ( $n \approx 45$ )

TRADEMARK

None as yet

SPONSOR

Sienna Biopharmaceuticals, Inc.

CODE DESIGNATIONS

CT327; SNA-120

CAS REGISTRY NUMBER

1233363-33-1

UNII

VG44NU1168

WHO NUMBER

10009

SCS